Athenex is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies to treat cancer. Our mission is to improve the lives of cancer patients by creating more effective, safer, and tolerable treatments. Our clinical pipeline drugs are based on our understanding of human absorption biology and novel approaches to inhibiting kinase activity. Our ability to overcome the challenges of oral delivery of chemotherapy and convert cornerstone therapies to the oral route offers significant potential benefits to patient outcomes.